Immunocore Holdings plc (IMCR)
About Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $400.0M
- Net income
- -$35.5M
- Total assets
- $1.1B
- Market cap
- $1.4B
- Gross margin
- 98.7%
- Operating margin
- -11.3%
- Net margin
- -8.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $400.0M
- Cost of revenue
- $5.1M
- Gross profit
- $394.9M
- Operating expenses
- $440.3M
- Operating income
- -$45.4M
- Income tax
- $16.4M
- Net income
- -$35.5M
- EPS (basic)
- $-0.71
- EPS (diluted)
- $-0.71
Balance sheet
- Total assets
- $1.1B
- Current assets
- $996.7M
- Total liabilities
- $686.2M
- Current liabilities
- $246.7M
- Shareholders’ equity
- $381.0M
Cash flow
- Operating cash flow
- -$10.7M
- Investing cash flow
- -$16.3M
- Financing cash flow
- $12.4M
- Net cash flow
- $12.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-0.71
- Shares outstanding
- 41.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 5, 2021
Immunocore Holdings plc (IMCR) Stock Price
- Reported a net loss of $35.5M in FY2025.
- Revenue grew 60% from FY2023 to FY2025.
- Gross margin of 98.7%, net margin -8.9%.
- Trading 13% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Immunocore Holdings plc.
Write a review
News about Immunocore Holdings plc
News & sentiment via Polygon.io
Immunocore Holdings plc: frequently asked questions
Is Immunocore Holdings plc an American company?
Immunocore Holdings plc is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Immunocore Holdings plc publicly traded?
Yes — Immunocore Holdings plc is a publicly traded company. Its stock trades under the ticker symbol IMCR on the NASDAQ.
What does Immunocore Holdings plc do?
Immunocore Holdings plc is an American Pharmaceuticals company in the Health & Beauty sector.
